赛雷普塔治疗公司(Sarepta Therapeutics)股价在夜盘交易中大幅下跌7.71%,延续了前一交易日的跌势,引发市场关注。
据报道,美国食品和药物管理局(FDA)要求赛雷普塔治疗公司暂停其产品Elevidys的分销。这一消息是导致公司股价持续下跌的主要原因。值得注意的是,在上一个交易日,该公司股价已经下跌了近36%。
Elevidys是赛雷普塔治疗公司的一款重要产品,主要用于治疗杜氏肌营养不良症。FDA的这一要求无疑对公司的业务运营和未来前景造成了重大影响。投资者对此反应强烈,导致股价在短期内出现大幅波动。市场将继续密切关注该公司与FDA之间的进一步沟通及Elevidys的未来发展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.